Thoracic SMARCA4-deficient undifferentiated tumors are rare, with poor prognosis. A 73-year-old man presented to our hospital with dyspnea. Computed tomography-guided biopsy revealed a SMARCA4-deficient undifferentiated tumor. The patient was treated with combination ipilimumab-nivolumab. The tumor reduced in size after two courses.

A case with non-small cell lung cancer exhibited extreme hyperglycemia after lorlatinib treatment, whose adverse effects on hyperglycemia is little known. But, the lorlatinib could be continued by intensifying diabetes treatment, indicating the importance of glucose monitoring during lorlatinib administration, and of adequate intensification of treatment for such hyperglycemia.